Target intelligence / Profile preview

Influenza A virus hemagglutinin group 1 stem domain (HA group 1 stem)

Target
HA group 1 stem
Molecular classification
Viral surface glycoprotein, Class I viral fusion protein, Trimeric type I transmembrane protein
01

Overview

The Influenza A hemagglutinin (HA) group 1 stem domain is a highly conserved structural region of the HA surface glycoprotein found in Group 1 influenza A viruses, which include subtypes such as H1, H2, H5, and H9 (Ekiert et al., 2009, Science). While the HA globular head mediates attachment to host sialic acid receptors and is subject to frequent antigenic drift, the stem domain is responsible for the critical step of membrane fusion (Bullough et al., 1994, Nature). Upon endocytosis, the acidic environment of the endosome triggers a massive conformational rearrangement in the stem that brings the viral and host membranes together, allowing the viral genome to enter the cytoplasm (Harrison, 2008, Nature Reviews Microbiology). Because of its high sequence conservation across different strains, the stem domain is the primary target for "universal" influenza vaccine strategies and broadly neutralizing monoclonal antibodies (bnAbs) like CR6261 and MEDI8852 (Corti et al., 2011, Science). These therapeutic agents typically function by binding to the stem and physically locking the protein in its pre-fusion state, preventing the pH-induced change required for infection (Kallewaard et al., 2016, Cell). Targeting this domain offers a promising avenue for providing broad-spectrum protection against both seasonal and emerging pandemic influenza threats.

Other names
Hemagglutinin stalk domainHA stemHA2 subunit (primary component)Influenza A group 1 HA stalkHemagglutinin stem region
02

Mechanism of action

Binding to the conserved stem region prevents the pH-triggered conformational change of hemagglutinin, thereby blocking the fusion of the viral envelope with the host endosomal membrane and preventing the release of the viral genome into the host cell cytosol.

03

Biological functions

Viral entryMembrane fusionEndosomal escapeConformational rearrangement
04

Disease associations

Influenza A infectionRespiratory tract infectionPandemic influenzaSeasonal influenza
05

Safety considerations

Immunodominance of the HA head domainPotential for antibody-dependent enhancement (ADE)Low natural immunogenicity of the stem domainRisk of viral escape mutants in the conserved pocket
06

Interacting drugs

CR6261

7 more in the full profile.

07

Biomarkers

Anti-HA stem antibody titers (ELISA)Microneutralization assay (MN)Viral load (RT-PCR)Stem-specific B-cell frequency

Beyond the preview

Go deeper on Influenza A virus hemagglutinin group 1 stem domain (HA group 1 stem).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus hemagglutinin group 1 stem domain (HA group 1 stem).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call